Evidence map›Paper›PMID 42305039›Full record

Trial reportAmerican journal of hematology2026

Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.

Stephen D Smith, Suchitra Sundaram, Sharmila Giri, Andy Ness, Yucai Wang, Ajay K Gopal, Yifan Pang, Emily Tamar Tatoian, Trenton Grossfeld, Ryan C Lynch and 3 more

Abstract readMulticenter StudyClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Stephen D SmithFred Hutchinson Cancer Center, Seattle, WA, USA.ORCID https://orcid.org/0000-0001-5354-7593
Suchitra SundaramMount Sinai Icahn School of Medicine, New York, New York, USA.
Sharmila GiriDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.
Andy NessDivision of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.
Yucai WangDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-1576-8341
Ajay K GopalFred Hutchinson Cancer Center, Seattle, WA, USA.ORCID https://orcid.org/0000-0003-3023-6834
Yifan PangDepartment of Cancer Medicine, Wake Forest University School of Medicine, Atrium Health, Charlotte, North Carolina, USA.
Emily Tamar TatoianMount Sinai Icahn School of Medicine, New York, New York, USA.
Trenton GrossfeldFred Hutchinson Cancer Center, Seattle, WA, USA.
Ryan C LynchFred Hutchinson Cancer Center, Seattle, WA, USA.
Edus H WarrenFred Hutchinson Cancer Center, Seattle, WA, USA.
Grzegorz S NowakowskiDivision of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Steven I ParkDepartment of Cancer Medicine, Wake Forest University School of Medicine, Atrium Health, Charlotte, North Carolina, USA.

Funding

AstraZeneca
6 · The paper itself

Abstract

First-line therapy for mantle cell lymphoma (MCL) represents a critical opportunity for clinical benefit via sustained complete response. We conducted a phase 2 multicenter trial in the academic and community cancer research united (ACCRU) network, testing a multitargeted 1st line regimen. CARiBOU (ACCRU-LY-1804) employs alternating VR-CAP and R-cytarabine with continuous acalabrutinib, in six 21-day cycles, for previously untreated MCL. The primary endpoint was complete metabolic response (CMR) rate. Secondary endpoints included safety, feasibility of stem cell collection, proportion proceeding to ASCT, and progression-free (PFS) and overall survival (OS). Peripheral blood measurable residual disease (MRD) was tested using the ClonoSEQ assay (Adaptive Biotechnologies). Of 41 patients enrolled, 39 (95%) responded to therapy, including 37 patients achieving CMR (90%). Two nonresponders discontinued therapy for toxicity early, prior to study-defined restaging, and received alternate therapy. Undetectable MRD at a 10

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Mantle-CellAdultAgedAged, 80 and overBenzamidesBortezomibCytarabineFemaleHumansMaleMiddle AgedPyrazinesRituximabTreatment OutcomeacalabrutinibBenzamidesBortezomibCytarabinePyrazinesRituximab

Identifiers

PMID42305039
PMCPMC13428400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.